Stoke Therapeutics, Inc. Common Stock STOK
i
Market dataready · fetched 2026-11-04T04:15:19.022Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-12-18
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-03T21:33:01.091508417Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-04T04:15:18.282968+00:00
Stoke Therapeutics, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | 21.62 | 142.4% | 29.1% | |||
| 30Δ | 23.47 | 117.5% | 22.4% | |||
| 35Δ | 25.15 | 95.9% | 16.4% | |||
| 40Δ | 25.97 | 89.9% | 14.3% | |||
| 45Δ | 29.92 | 94.4% | 20.2% | 26.80 | 83.9% | 12.2% |
| 50Δ | 28.87 | 87.6% | 17.0% | 27.62 | 77.8% | 10.1% |
| 55Δ | 27.82 | 80.8% | 13.9% | 28.45 | 71.8% | 8.0% |
| 60Δ | 26.77 | 74.0% | 10.8% | 29.27 | 65.8% | 5.9% |
| 65Δ | 25.73 | 67.2% | 7.7% | |||
| 70Δ | 24.71 | 63.0% | 5.2% | |||
| 75Δ | 23.78 | 64.7% | 4.3% | |||
| 80Δ | 22.85 | 66.4% | 3.4% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 21.62
- IV
- 142.4%
- B/E move
- 29.1%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 23.47
- IV
- 117.5%
- B/E move
- 22.4%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 25.15
- IV
- 95.9%
- B/E move
- 16.4%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 25.97
- IV
- 89.9%
- B/E move
- 14.3%
45Δ
- Pseudo strike
- 29.92
- IV
- 94.4%
- B/E move
- 20.2%
- Pseudo strike
- 26.80
- IV
- 83.9%
- B/E move
- 12.2%
50Δ
- Pseudo strike
- 28.87
- IV
- 87.6%
- B/E move
- 17.0%
- Pseudo strike
- 27.62
- IV
- 77.8%
- B/E move
- 10.1%
55Δ
- Pseudo strike
- 27.82
- IV
- 80.8%
- B/E move
- 13.9%
- Pseudo strike
- 28.45
- IV
- 71.8%
- B/E move
- 8.0%
60Δ
- Pseudo strike
- 26.77
- IV
- 74.0%
- B/E move
- 10.8%
- Pseudo strike
- 29.27
- IV
- 65.8%
- B/E move
- 5.9%
65Δ
- Pseudo strike
- 25.73
- IV
- 67.2%
- B/E move
- 7.7%
- Pseudo strike
- IV
- B/E move
70Δ
- Pseudo strike
- 24.71
- IV
- 63.0%
- B/E move
- 5.2%
- Pseudo strike
- IV
- B/E move
75Δ
- Pseudo strike
- 23.78
- IV
- 64.7%
- B/E move
- 4.3%
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- 22.85
- IV
- 66.4%
- B/E move
- 3.4%
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 77.26% | |
| 73.36% | |
| 77.07% | |
| 75.71% | |
| 77.24% | |
| 74.85% | |
| 80.45% | |
| 82.01% | |
| 79.35% | |
| 75.45% |
Biotechnology
STRO
Sutro Biopharma, Inc. is a clinical stage drug discovery, development and manufacturing company. The company is headquartered in South San Francisco, California.
More →STTK
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapies for the treatment of cancer and autoimmune diseases in the United States. The company is…
More →SVRA
Savara Inc. is a lung disease orphan company. The company is headquartered in Austin, Texas.
More →SYRE
Spyre Therapeutics, Inc., a biotechnology company, focuses on advancing a pipeline of antibody therapeutics for the treatment of inflammatory bowel disease by combining antibody…
More →TARA
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to identifying and promoting transformative therapies for the treatment of cancer and rare…
More →TARS
Description unavailable
More →